Clinical trial Recruiting at 2 sites Interventional Ages 18 to 50 Women only

Cervical cerclage for preventing premature birth in high-risk pregnancies

Official title: Cervical Cerclage for Short Cervix at 24-26 Weeks of Gestation: a Randomized Controlled Trial

Run by Thomas Jefferson University · NCT06036446 · Data updated 2026-11-12

This study is testing if a procedure called cervical cerclage can help prevent early birth in pregnant people who are at high risk due to a short cervix.

Quick facts

Study typeInterventional
Ages18 Years to 50 Years
SexWomen only
Enrollment329 (estimated)
SponsorThomas Jefferson University
Academic / other
Locations2 sites (Charlotte, North Carolina and 1 other locations)
StatusRecruiting
StartedNovember 10, 2023
Main results expectedOctober 2028
Study endsFebruary 2029
Registry record updatedMay 29, 2026
Trial IDNCT06036446 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are pregnant individuals aged 18-50 with singleton pregnancies and a cervical length of 25mm or less between 24 and 26 weeks of gestation.

Probably not a fit

Patients with multifetal pregnancies, active preterm labor, or other contraindications to cerclage placement may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of cervical cerclage in reducing the risk of preterm birth among singleton pregnancies identified as high-risk due to a short cervical length of 25mm or less. Pregnant individuals between 24 and 26 weeks of gestation will be screened and randomized to receive either cervical cerclage or no cerclage, while all participants will also be recommended to use vaginal progesterone. The primary outcome measured will be the incidence of preterm birth before 37 weeks of gestation. This approach seeks to provide a potential intervention for those at significant risk of early delivery.

Why it matters

Potential benefit: If successful, this intervention could significantly reduce the incidence of preterm births in high-risk pregnancies.

How similar studies have gone: Previous studies have shown varying degrees of success with cervical cerclage in preventing preterm birth, making this approach both relevant and potentially impactful.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* 18-50 years old, pregnant, assigned female at birth
* Singleton pregnancy
* TVU CL ≤25mm between 24 0/7 - 26 6/7 weeks of gestation

Exclusion Criteria:

* Initial multifetal gestation with subsequent multifetal pregnancy reduction, or selective fetal termination performed \>14 weeks, or cotwin pregnancy loss diagnosed \>14 weeks
* Cerclage in situ
* Preterm labor, defined as painful regular uterine contractions and change in cervical dilation
* PPROM
* Active vaginal bleeding
* Suspected intraamniotic infection
* Major fetal structural abnormality or chromosomal disorder
* Placenta previa or accreta
* Other contraindication to cerclage placement
* Participation in another clinical trial related to preterm birth prevention, cerclage, or progesterone

Where it's running

  • Atrium Health Carolinas Medical Center
    Charlotte, North Carolina, United States
    Recruiting
  • Thomas Jefferson University
    Philadelphia, Pennsylvania, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.